Nuzenio

Level Phase

Level Phase news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 8 latest news signals 5 publisher sources 100/100 entity strength

Latest news

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF - Investing News NetworkInvesting News Network · Mon, 10 Aug 2026 12:54:11 GMTTenax Therapeutics (NASDAQ:TENX) Drops 85% as Phase 3 LEVEL Study Fails to Meet Main Endpoints - TechStock²TechStock² · Mon, 10 Aug 2026 12:46:29 GMTTenax Therapeutics reports Phase 3 LEVEL topline: missed primary but strong biomarker and subgroup signals - TradingViewTradingView · Mon, 10 Aug 2026 11:23:01 GMTOrion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint - The Manila TimesThe Manila Times · Mon, 10 Aug 2026 11:19:58 GMTTENX: LEVEL Phase 3 showed TNX-103 benefits patients with higher disease burden, guiding next steps - TradingViewTradingView · Mon, 10 Aug 2026 11:17:12 GMTTenax Therapeutics Phase 3 Level Trial Misses Primary Endpoint - TradingViewTradingView · Mon, 10 Aug 2026 11:09:24 GMTNest-Level Phase Transition Drives Synchronized Activity Bursts in Ant Colonies - APS JournalsAPS Journals · Wed, 05 Aug 2026 17:20:25 GMTTenax Therapeutics reports Q2 net loss $17.8M, cash $118.0M; LEVEL Phase 3 topline due Aug 2026 - TradingViewTradingView · Fri, 31 Jul 2026 11:33:00 GMT

Timeline

Mon, 10 Aug 2026 12:54:11 GMTTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF - Investing News Network
Mon, 10 Aug 2026 12:46:29 GMTTenax Therapeutics (NASDAQ:TENX) Drops 85% as Phase 3 LEVEL Study Fails to Meet Main Endpoints - TechStock²
Mon, 10 Aug 2026 11:23:01 GMTTenax Therapeutics reports Phase 3 LEVEL topline: missed primary but strong biomarker and subgroup signals - TradingView
Mon, 10 Aug 2026 11:19:58 GMTOrion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint - The Manila Times
Mon, 10 Aug 2026 11:17:12 GMTTENX: LEVEL Phase 3 showed TNX-103 benefits patients with higher disease burden, guiding next steps - TradingView
Mon, 10 Aug 2026 11:09:24 GMTTenax Therapeutics Phase 3 Level Trial Misses Primary Endpoint - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Level Phase.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

5 distinct publisher/source names are currently connected to this entity page.